Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CLDX's Cash-to-Debt is ranked higher than
98% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CLDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CLDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.52  Med: 264.75 Max: No Debt
Current: No Debt
Equity-to-Asset 0.69
CLDX's Equity-to-Asset is ranked higher than
53% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLDX: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
CLDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.12  Med: 0.83 Max: 0.92
Current: 0.69
-0.12
0.92
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
97% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -0.95
Beneish M-Score: -0.45
WACC vs ROIC
20.63%
-558.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1958.95
CLDX's Operating Margin % is ranked lower than
83% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CLDX: -1958.95 )
Ranked among companies with meaningful Operating Margin % only.
CLDX' s Operating Margin % Range Over the Past 10 Years
Min: -3414.11  Med: -878.49 Max: -13.79
Current: -1958.95
-3414.11
-13.79
Net Margin % -1894.33
CLDX's Net Margin % is ranked lower than
83% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CLDX: -1894.33 )
Ranked among companies with meaningful Net Margin % only.
CLDX' s Net Margin % Range Over the Past 10 Years
Min: -3292.81  Med: -854.57 Max: -5.41
Current: -1894.33
-3292.81
-5.41
ROE % -50.71
CLDX's ROE % is ranked lower than
60% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CLDX: -50.71 )
Ranked among companies with meaningful ROE % only.
CLDX' s ROE % Range Over the Past 10 Years
Min: -2929.64  Med: -56.47 Max: -3.4
Current: -50.71
-2929.64
-3.4
ROA % -41.57
CLDX's ROA % is ranked lower than
60% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CLDX: -41.57 )
Ranked among companies with meaningful ROA % only.
CLDX' s ROA % Range Over the Past 10 Years
Min: -120  Med: -41.12 Max: -2.02
Current: -41.57
-120
-2.02
ROC (Joel Greenblatt) % -1132.29
CLDX's ROC (Joel Greenblatt) % is ranked lower than
63% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CLDX: -1132.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1193.97  Med: -658.84 Max: -10.72
Current: -1132.29
-1193.97
-10.72
3-Year Revenue Growth Rate 8.80
CLDX's 3-Year Revenue Growth Rate is ranked higher than
57% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CLDX: 8.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CLDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -67.2  Med: -23.5 Max: 105.6
Current: 8.8
-67.2
105.6
3-Year EBITDA Growth Rate 9.20
CLDX's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CLDX: 9.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.2  Med: -2.1 Max: 53.7
Current: 9.2
-32.2
53.7
3-Year EPS without NRI Growth Rate 7.60
CLDX's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CLDX: 7.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.6  Med: 1.4 Max: 163.4
Current: 7.6
-64.6
163.4
GuruFocus has detected 3 Warning Signs with Celldex Therapeutics Inc $CLDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLDX's 10-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CLDX Guru Trades in Q1 2016

John Paulson 70,800 sh (New)
Jim Simons 813,331 sh (New)
Paul Tudor Jones 139,437 sh (+779.34%)
First Eagle Investment 629,542 sh (+8.63%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 2,976,400 sh (-17.55%)
» More
Q2 2016

CLDX Guru Trades in Q2 2016

Columbia Wanger 5,261,934 sh (+76.79%)
John Paulson 70,800 sh (unchged)
Murray Stahl 26,335 sh (unchged)
Jim Simons 776,800 sh (-4.49%)
First Eagle Investment 445,000 sh (-29.31%)
Paul Tudor Jones 15,137 sh (-89.14%)
» More
Q3 2016

CLDX Guru Trades in Q3 2016

Jim Simons 1,258,214 sh (+61.97%)
Murray Stahl 26,335 sh (unchged)
John Paulson 70,800 sh (unchged)
First Eagle Investment 445,000 sh (unchged)
Paul Tudor Jones 13,406 sh (-11.44%)
Columbia Wanger 2,907,523 sh (-44.74%)
» More
Q4 2016

CLDX Guru Trades in Q4 2016

Paul Tudor Jones 47,806 sh (+256.60%)
Columbia Wanger 6,195,855 sh (+113.10%)
John Paulson 70,800 sh (unchged)
Murray Stahl 26,335 sh (unchged)
First Eagle Investment Sold Out
Jim Simons 1,199,710 sh (-4.65%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:BSTC, OTCPK:ZLDPF, NAS:CRIS, NAS:AVDL, NAS:MACK, NAS:BLCM, AMEX:BTX, NAS:CALA, NAS:CNCE, NAS:PDLI, NAS:MRUS, NAS:MYOK, NAS:CRBP, NAS:BOLD, NAS:SYRS, NAS:AGEN, NAS:OTIC, NAS:SGMO, NAS:IDRA, OTCPK:ABVC » details
Traded in other countries:TCE1.Germany,
Headquarter Location:USA
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. Its stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as EGFRvIII. Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. It established proof of concept in a Phase 1 study with varlilumab, which has allowed several combination studies to begin in various indications. The Company is a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Its clinical development programs include Rintega, Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, CDX-014. The Company relies on contract manufacturing organizations, or CMOs, to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. It also relies on CMOs for filling and packaging, labeling, storage and shipping of drug product. The Company own or license rights under more than 300 granted patents and national and regional patent applications in the U.S. and in international territories covering inventions relating to its business. Competitors that the Company is aware of that have initiated a Phase 3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Novartis, Novocure, Pfizer Inc., and Roche.

Top Ranked Articles about Celldex Therapeutics Inc

Celldex Therapeutics Announces Appointment to Board of Directors

HAMPTON, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of James J. Marino, J.D., to the Company’s Board of Directors. Mr. Marino was with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office. His practice focused on the representation of leading life sciences companies, both privately- and publicly-held, in a broad range of corporate, transactional and finance matters. He will serve as the Chairman of the Compensation Committee.
“Jim’s wealth of experience advising numerous life science companies provides us additional perspective on the current healthcare business environment,” said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. “His knowledge and guidance will be important to Celldex as we advance our pipeline through clinical development and explore multi-drug combinations to address unmet patient needs.” Mr. Marino currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center and on the Board of Directors of Onconova Therapeutics, Inc. He previously served on the Board of Directors of Pharmacopeia, Inc. He has also worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. Additionally, Mr. Marino is a co-founder of BioNJ, the trade association of biotechnology companies based in New Jersey, which he represented from its inception. Mr. Marino received his B.A., his M.B.A. and his J.D. from Rutgers University. About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com. Forward Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization of our drug candidates and our future goals. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of our drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to successfully integrate our and the recently acquired business of Kolltan Pharmaceuticals, and to operate the combined businesses efficiently; our ability to realize the anticipated benefits from the acquisition of Kolltan; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
[email protected]  

Charles Liles
Associate Director of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.45
CLDX's PB Ratio is ranked higher than
80% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CLDX: 1.45 )
Ranked among companies with meaningful PB Ratio only.
CLDX' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 4.86 Max: 50.74
Current: 1.45
1.23
50.74
PS Ratio 48.06
CLDX's PS Ratio is ranked lower than
78% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CLDX: 48.06 )
Ranked among companies with meaningful PS Ratio only.
CLDX' s PS Ratio Range Over the Past 10 Years
Min: 1.67  Med: 47.27 Max: 975.38
Current: 48.06
1.67
975.38
EV-to-EBIT -1.94
CLDX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CLDX: -1.94 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77.2  Med: -3.8 Max: 0.3
Current: -1.94
-77.2
0.3
EV-to-EBITDA -2.00
CLDX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CLDX: -2.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -515.4  Med: -3.6 Max: 39.2
Current: -2
-515.4
39.2
Current Ratio 5.55
CLDX's Current Ratio is ranked higher than
60% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CLDX: 5.55 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.56 Max: 15
Current: 5.55
0.56
15
Quick Ratio 5.55
CLDX's Quick Ratio is ranked higher than
61% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CLDX: 5.55 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.56 Max: 15
Current: 5.55
0.56
15
Days Sales Outstanding 95.97
CLDX's Days Sales Outstanding is ranked lower than
70% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CLDX: 95.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 38.85 Max: 95.97
Current: 95.97
1.43
95.97

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
CLDX's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CLDX: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.1  Med: -15.8 Max: 0
Current: -10.5
-73.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.37
CLDX's Price-to-Net-Cash is ranked higher than
53% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CLDX: 5.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.94  Med: 7.44 Max: 22.34
Current: 5.37
2.94
22.34
Price-to-Net-Current-Asset-Value 5.03
CLDX's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CLDX: 5.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.77  Med: 6.29 Max: 16.63
Current: 5.03
2.77
16.63
Price-to-Tangible-Book 4.18
CLDX's Price-to-Tangible-Book is ranked lower than
53% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CLDX: 4.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.07  Med: 4.76 Max: 10.26
Current: 4.18
2.07
10.26
Price-to-Median-PS-Value 1.02
CLDX's Price-to-Median-PS-Value is ranked lower than
65% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CLDX: 1.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 0.6 Max: 9.86
Current: 1.02
0.06
9.86
Earnings Yield (Greenblatt) % -51.51
CLDX's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CLDX: -51.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -133.6  Med: 137.6 Max: 22667
Current: -51.51
-133.6
22667

More Statistics

Revenue (TTM) (Mil) $6.79
EPS (TTM) $ -1.26
Beta3.07
Short Percentage of Float24.46%
52-Week Range $2.85 - 5.13
Shares Outstanding (Mil)123.21

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3 3 5
EPS ($) -1.30 -1.37 -1.58
EPS without NRI ($) -1.30 -1.37 -1.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Celldex Therapeutics Announces Appointment to Board of Directors Mar 01 2017 
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
Read This Before You Buy Biotech Stocks Apr 23 2017
Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum... Apr 21 2017
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Apr 20 2017
What's in Store for Biogen (BIIB) this Earnings Season? Apr 20 2017
ETFs with exposure to Celldex Therapeutics, Inc. : April 19, 2017 Apr 19 2017
Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report? Apr 19 2017
3 Cancer Drug Stocks That Could Make You Rich Apr 17 2017
3 Biotech Stocks to Buy on Sale Apr 15 2017
3 Stocks That Could Double Your Money Apr 07 2017
3 Top Stocks You've Been Overlooking Apr 01 2017
Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Mar 31 2017
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March... Mar 30 2017
ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017 Mar 27 2017
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat Mar 15 2017
Edited Transcript of CLDX earnings conference call or presentation 14-Mar-17 8:30pm GMT Mar 14 2017
Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing Mar 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)